BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou Y, Yang X, Liu H, Luo W, Liu H, Lv T, Wang J, Qin J, Ou S, Chen Y. Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis. Eur J Nucl Med Mol Imaging 2021;48:3493-501. [PMID: 33829416 DOI: 10.1007/s00259-021-05343-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, Calais J. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol 2023;96:20220463. [PMID: 35776566 DOI: 10.1259/bjr.20220463] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
2 Liu H, Yang X, You Z, Hu Z, Chen Y. Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer. Nuklearmedizin 2023;62:38-44. [PMID: 36746149 DOI: 10.1055/a-1984-8044] [Reference Citation Analysis]
3 Chen L, Zhong X, Li L, Li X, Liu Y, Guo C, Chen Y, Huang Z. [(68)Ga]Ga-FAPI-04 PET/CT on assessing Crohn's disease intestinal lesions. Eur J Nucl Med Mol Imaging 2023. [PMID: 36631715 DOI: 10.1007/s00259-023-06107-5] [Reference Citation Analysis]
4 He Y, Zhou Y, Wu W, Chen Y, Ou S. Bartter syndrome with multiple renal and liver cysts: a case report. Int Urol Nephrol 2023;55:225-8. [PMID: 35768702 DOI: 10.1007/s11255-022-03274-6] [Reference Citation Analysis]
5 Beyhan E, Erol Fenercioğlu Ö, Yarikkaya E, Çermik TF, Ergül N. Chronic Gastritis Mimicking Malignancy on 68 Ga-FAPI-04 PET/CT. Clin Nucl Med 2023;48:e37-9. [PMID: 36240789 DOI: 10.1097/RLU.0000000000004439] [Reference Citation Analysis]
6 Barton AK, Tzolos E, Bing R, Singh T, Weber W, Schwaiger M, Varasteh Z, Slart RHJA, Newby DE, Dweck MR. Emerging molecular imaging targets and tools for myocardial fibrosis detection. Eur Heart J Cardiovasc Imaging 2022:jeac242. [PMID: 36575058 DOI: 10.1093/ehjci/jeac242] [Reference Citation Analysis]
7 Li Y, Deng L, Feng Y, Chen Y, Lv F, Qiu L. Potential utility of 68Ga-DOTA-FAPI-04 as a broad-spectrum benign disease imaging agent—comparison with 18F-FDG and 99mTc-MDP.. [DOI: 10.21203/rs.3.rs-2368208/v1] [Reference Citation Analysis]
8 Glatting FM, Hoppner J, Liew DP, van Genabith A, Spektor AM, Steinbach L, Hubert A, Kratochwil C, Giesel FL, Dendl K, Rathke H, Kauczor HU, Huber PE, Haberkorn U, Röhrich M. Repetitive Early (68)Ga-FAPI PET Acquisition Comparing (68)Ga-FAPI-02, (68)Ga-FAPI-46, and (68)Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions. J Nucl Med 2022;63:1844-51. [PMID: 35618480 DOI: 10.2967/jnumed.122.264069] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Schmidkonz C, Kuwert T, Atzinger A, Cordes M, Schett G, Ramming A, Götz T. Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging. J Nucl Med 2022;63:1786-92. [PMID: 36109182 DOI: 10.2967/jnumed.122.264205] [Reference Citation Analysis]
10 Glatting FM, Hoppner J, Kauczor H, Huber PE, Kratochwil C, Giesel FL, Haberkorn U, Röhrich M. Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74. Cancers 2022;14:5301. [DOI: 10.3390/cancers14215301] [Reference Citation Analysis]
11 Liu H, Hu Z, Yang X, Dai T, Chen Y. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG Uptake in Esophageal Cancer. Front Oncol 2022;12:875081. [DOI: 10.3389/fonc.2022.875081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Meng L, Fang J, Zhao L, Wang T, Yuan P, Zhao Z, Zhuang R, Lin Q, Chen H, Chen X, Zhang X, Guo Z. Rational Design and Pharmacomodulation of Protein-Binding Theranostic Radioligands for Targeting the Fibroblast Activation Protein. J Med Chem 2022. [PMID: 35658448 DOI: 10.1021/acs.jmedchem.1c02162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kou Y, Jiang X, Yao Y, Shen J, Jiang X, Chen S, Lu H, Wang X, Zhao M, Xiao D, Shen T, Zhang W, Cheng Z. Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET/CT imaging. Nucl Med Commun 2022. [PMID: 35506283 DOI: 10.1097/MNM.0000000000001563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Gong W, Fu M, Zhang Y, Yang X, Zhang C. Progressive Multifocal Leukoencephalopathy Mimicking Malignancy on 68Ga-FAPI PET/CT: Potential Advantages of FAPI. Clin Nucl Med 2022;47:430-2. [PMID: 35020663 DOI: 10.1097/RLU.0000000000003976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Roustaei H, Kiamanesh Z, Askari E, Sadeghi R, Aryana K, Treglia G. Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents? Contrast Media Mol Imaging 2022;2022:3948873. [PMID: 35280710 DOI: 10.1155/2022/3948873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Gong W, Chen S, He L, Liu W, Zhang C. Intense 68Ga-FAPI Uptake in a Patient With Myositis Ossificans: Mimicking Bone Malignancy. Clin Nucl Med 2022;Publish Ahead of Print. [DOI: 10.1097/rlu.0000000000004213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Gong W, Yang X, Mou C, Liu H, Zhang C. Bone Tuberculous Granulomatous Inflammation Mimicking Malignancy on 68Ga-FAPI PET/CT. Clin Nucl Med 2022;47:348-9. [PMID: 35020664 DOI: 10.1097/RLU.0000000000003990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05706-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
19 Yang T, Ma L, Hou H, Gao F, Tao W. FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors. Front Oncol 2021;11:797960. [PMID: 35059319 DOI: 10.3389/fonc.2021.797960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Werner RA, Pomper MG, Buck AK, Rowe SP, Higuchi T. SPECT and PET Radiotracers in Renal Imaging. Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2021.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Liu H, Yang X, Liu L, Lei L, Wang L, Chen Y. Clinical Significance of Diffusely Increased Uptake of 68Ga-FAPI in Thyroid Gland. Front Med (Lausanne) 2021;8:782231. [PMID: 34888332 DOI: 10.3389/fmed.2021.782231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Cimini A, Ricci M, Gigliotti PE, Pugliese L, Chiaravalloti A, Danieli R, Schillaci O. Medical Imaging in the Diagnosis of Schistosomiasis: A Review. Pathogens 2021;10:1058. [PMID: 34451522 DOI: 10.3390/pathogens10081058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]